WO2002017962A9 - Agent de chimio-prevention contre la toxicite gastrique - Google Patents

Agent de chimio-prevention contre la toxicite gastrique

Info

Publication number
WO2002017962A9
WO2002017962A9 PCT/US2001/027296 US0127296W WO0217962A9 WO 2002017962 A9 WO2002017962 A9 WO 2002017962A9 US 0127296 W US0127296 W US 0127296W WO 0217962 A9 WO0217962 A9 WO 0217962A9
Authority
WO
WIPO (PCT)
Prior art keywords
agent
pharmaceutical composition
side effects
treatment
mitigating
Prior art date
Application number
PCT/US2001/027296
Other languages
English (en)
Other versions
WO2002017962A3 (fr
WO2002017962A2 (fr
Inventor
Edward A Neuwelt
Leslie Muldoon
Original Assignee
Univ Oregon Health & Science
Edward A Neuwelt
Leslie Muldoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Edward A Neuwelt, Leslie Muldoon filed Critical Univ Oregon Health & Science
Priority to AU2001287021A priority Critical patent/AU2001287021A1/en
Priority to US10/363,150 priority patent/US20040062764A1/en
Priority to EP01966515A priority patent/EP1365803A2/fr
Priority to CA002420897A priority patent/CA2420897A1/fr
Publication of WO2002017962A2 publication Critical patent/WO2002017962A2/fr
Publication of WO2002017962A9 publication Critical patent/WO2002017962A9/fr
Publication of WO2002017962A3 publication Critical patent/WO2002017962A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Definitions

  • the invention provides chemoprotectant agents that may be administered in conjunction with cytotoxic agents that target carcinoma type cancers. More particularly, the cytotoxic agent targets Lewis Y glycoproteins on gastric epithelium, with or without addition of conventional chemotherapeutic agents. Intra-arterial administration of a thiol- based chemoprotective agent will target the cytotoxic agent to reduce immunoconjugate and chemotherapy side effects without decreasing anti-tumor efficacy.
  • NAC N-acetylcysteine
  • cysteine is an analog of cysteine with strong anti-oxidant and free radical scavenging activity.
  • NAC is deacylated and enters a cellular synthetic pathway for production of glutathione.
  • Glutathione is involved in many cellular processes that may have importance for the resistance of tumors to cytotoxic drugs, including anti-oxidant, drug conjugation, and drug extrusion.
  • NAC can mimic short term effects of glutathione as well as increasing glutathione for later protective activity.
  • thiol-based chemoprotectant agents that contain a thio, thiol, aminothiol or thioester moiety. These include N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, and Ethyol (WR2721). Ethyol is also marketed in the United ' States under the generic name of Amifostine. GSH ethyl ester is an experimental thiol not yet marketed for clinical use, but is representative of the class of thiols that is converted directly to glutathione.
  • NAC is currently marketed in the United States under an orphan indication for oral and intra venous (iv) administration for overdosing with acetaminophen.
  • NAC has also been shown to be a chemoprotectant when administered in combination with a vanadate compound (U.S. Patent 5,843,481; and Yarbo (ed) Semin. Oncol. 10 [Suppl 1]56-61, 1983).
  • NAC has been shown to be a mucoregulatory drug used for the treatment of chronic bronchitis (Grassi and Morandini, Eur. J. Clin. Pharmacol. 9:393- 396, 1976; Multicenter Study Group, Eur. J. Respir. Dis. 61: [Su ⁇ pl.]93-108, 1980; and Borman et al., Eur. J. Respir. Dis. 64:405-415, 1983).
  • NAC can be present in its intact, reduced forms as well as in various oxidized forms. It can be oxidized to a disulfide by reacting with other low molecular weight thiols, such as cysteine and glutathione. NAC can be oxidized by reaction the thiol groups of plasma proteins.
  • thiols such as cysteine and glutathione.
  • NAC can be oxidized by reaction the thiol groups of plasma proteins.
  • NAC cysteine and cystine have been identified as major metabolites of NAC.
  • the excreted urinary product was inorganic sulfate together with small amounts of taurine and unchanged NAC.
  • vials of NAC are produced as a sterile solution for oral administration diluted with water or soft drinks.
  • NAC is initially diluted in the venous pool when administered iv and then rapidly eliminated from the systemic circulation by the liver. Thus, very little of the initial dose of NAC is available to systemic tissues for entry into the glutathione pathway and potential chemoprotection.
  • STS sodium thiosulfate
  • STS sodium thiosulfate
  • Its chemical formula Na 2 S 2 O 3 and it has been used clinically for cyanide poisoning and for nephrotoxicity caused by cisplatin.
  • STS is cleared rapidly from circulation primarily by the kidney. The plasma half life after a bolus injection is about 17 minutes.
  • STS can also inactivate platinum agents due to a covalent binding to platinum agents at molar excess >40:1 (STS:platinum).
  • STS is currently used as a chemoprotectant against carboplatin chemotherapy-induced hearing loss (Neuwelt, JPET 1998).
  • Tumor selective monoclonal antibodies can be used as delivery systems for chemotherapeutic agents, toxins, and enzyme prodrug therapies based on their potential to discriminate neoplastic cell populations relative to normal tissues.
  • a murine mAb, BR96 (IgGl) has been developed which binds to a Lewis Y (Le y )-related antigen abundantly expressed at the surface of cells from carcinomas of the lung, breast, ovary and colon while having low reactivity with most normal human tissues (Trail et al., Cancer Res. 52:5693-5700, 1992; Trail et al., Science 261:212-215, 1993. Remsen et al., Neurosurgery, 46:704-709, 2000).
  • the BR96 antibody was conjugated to doxorubicin (DOX) to produce a targeted immunoconjugate.
  • DOX is a broad spectrum antitumor agent frequently used in the treatment of leukemia, breast carcinoma and other cancers, but its efficacy is limited by dose dependent toxicities including bone marrow suppression and cardiotoxicity.
  • the conjugation of the drug to the antibody produced an immunoconjugate, BR96-DOX, with reduced systemic toxicity, and with high specificity against carcinomas that express the Lewis Y antigen.
  • BR96-DOX has been shown to be an effective and safe agent against several tumor types growing as subcutaneous transplants in animal models including human lung adenocarcinoma, colon carcinoma, and breast carcinoma.
  • BR96-DOX in combination with conventional chemotherapeutic agents such as carboplatin or Taxol (pacletaxel), has synergistic antitumor effect.
  • Next generation antibodies targeting the Lewis Y antigen should also be effective immunoconjugates.
  • BR96-DOX gastro-intestinal toxicity or gastritis (Seleh et al., J Clin. Oncol. 2000). Similar gastritis can be expected from any immunoconjugate that targets the Lewis Y antigen. This GI toxicity must be reduced for this effective experimental approach to be successful in clinical trials.
  • Immunoconjugate toxicity may be increased by combination with conventional chemotherapy.
  • conventional chemotherapy does not induce gastritis on its own.
  • NAC protects against chemotherapy induced systemic toxicity, not inclusive of gastric toxicity.
  • a method for treating or mitigating the side effects of a cytotoxic cancer therapy for carcinoma type cancers is described.
  • One or a plurality of cytotoxic agents and a thiol- based chemoprotectant agent are administered intra-arterially, wherein the intra-arterial administration is through a catheter placed into an artery that provides blood flow to an organ most susceptible to toxic side effects of the cytotoxic agent.
  • the thiol-based chemoprotectant agent is a compound selected from the group consisting of N- acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof.
  • the cytotoxic agent is selected from the group consisting of chimeric anti-Lewis Y monoclonal antibodies conjugated to a cytotoxic agent, used either alone or in combination with unconjugated, platinum compounds, taxanes (e.g., paclitaxel), steroid derivatives, anti-metabolites, vinca alkaloids, adriamycin and doxarubicin, etoposide, arsenic derivatives, intercalating agents, alkylating agents (e.g., melphalan) and combinations thereof.
  • the cytotoxic agent is a monoclonal antibody to the Lewis Y glycoprotein.
  • the monoclonal antibody is BR96-Doxorubicin.
  • the dose of the thiol- based chemoprotectant agent per procedure is from about 200 mg/m 2 to about 40 g/m 2 .
  • the daily dose of NAC agent during chemotherapy is from about 400 mg/m to about 1200 mg/m .
  • a pharmaceutical composition for treatment of carcinoma type cancers for administration via arterial catheter including a first agent that is a cancer cytotoxic agent and a second agent administered intra-arterially is disclosed, wherein the first agent is a cytotoxic compound that is used for cancer chemotherapy but is dose-limited due to side effects, and the second agent is a thiol-based chemoprotectant agent.
  • the first agent is selected from the group consisting of chimeric anti-Lewis Y monoclonal antibodies conjugated to a cytotoxic agent used either alone or in combination with unconjugated, platinum compounds, taxanes (e.g., paclitaxel), steroid derivatives, anti- metabolites, vinca alkaloids, adriamycin and doxarubicin, etoposide, arsenic derivatives, intercalating agents, alkylating agents (such as melphalan), and combinations thereof.
  • the chimeric monoclonal antibody is BR96-Doxorubicin.
  • the second agent is administered in a pyrogen-free sterile solution.
  • the second agent is administered in a pyrogen-free, non-oxidized sterile solution having a reducing agent, and optionally a buffer to maintain pH at or near physiologic pH and optionally a metal chelating agent to bind up metal ions that can catalyze oxidation of the thiol-based chemoprotectant agent.
  • the thiol-based chemoprotectant agent is stored in a vial having a blanket of an inert gas.
  • the inert gas is selected from the group consisting of argon, helium, nitrogen and mixtures thereof.
  • the reducing agent is selected from the group consisting of vitamin E, tocoperol, dithiothreatal, mercaptoethanol, glutathione, and combinations thereof.
  • the buffer is one that is relatively non-toxic and can maintain a pH of between 6 and 8 (e.g., phosphate buffer, Tris buffer, Ringers solution, and the like).
  • the thiol-based chemoprotectant agent is a compound selected from the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof.
  • the daily dose of the thiol-based chemoprotectant agent during chemotherapy is from about 200 mg/m 2 to about 2000 mg/m 2 .
  • the dose of NAC per procedure is from about 400 mg/m 2 to about 1200 mg/m 2 .
  • a pharmaceutical composition for mitigating the gastrointestinal side effects from treatment of carcinoma type cancers with agents that bind to the Lewis Y antigen (administered alone, in combination with other cytotoxic agents, or conjugated to other cytotoxic agents) for administration via arterial catheter including an agent administered intra-arterially, wherein the agent is a thiol-based chemoprotectant agent.
  • the Lewis Y antigen binding agent is a chimeric monoclonal antibody, optionally conjugated to a cytotoxic agent, and used either alone or in combination with unconjugated, platinum compounds, taxanes (e.g., paclitaxel), steroid derivatives, anti- metabolites, vinca alkaloids, adriamycin and doxorubicin, etoposide, arsenic derivatives, intercalating agents, alkylating agents (such as melphalan), and combinations thereof.
  • the chimeric monoclonal antibody is BR96-Doxorubicin.
  • the agent is administered in a pyrogen-free sterile solution
  • the agent is administered in a pyrogen-free, non-oxidized sterile solution having a reducing agent, and optionally a buffer to maintain pH at or near physiologic pH and optionally a metal chelating agent to bind up metal ions that can catalyze oxidation of the thiol-based chemoprotectant agent.
  • the thiol-based chemoprotectant agent is stored in a vial having a blanket of an inert gas.
  • the inert gas is selected from the group consisting of argon, helium, nitrogen and mixtures thereof.
  • the reducing agent is selected from the group consisting of vitamin E, tocoperol, dithiothreatal, mercaptoethanol, glutathione, and combinations thereof.
  • the buffer is one that is relatively non-toxic and can maintain a pH of between 6 and 8 (e.g., phosphate buffer, Tris buffer, Ringers solution, and the like).
  • the thiol-based chemoprotectant agent is a compound selected from the group consisting of N-acetyl cysteine (NAC), sodium thiosulfate (STS), GSH ethyl ester, D-methionine, Ethyol, and combinations thereof.
  • the daily dose of the thiol-based chemoprotectant agent during chemotherapy is from about 200 mg/m 2 to about 2000 mg/m 2 .
  • the dose of NAC per procedure is from about 400 mg/m 2 to about 1200 mg/m 2 .
  • Figure 1 shows a graph representing the efficacy of BR96-DOX against human small cell lung carcinoma cells implanted in the brain of the nude rat.
  • Figure 2a shows a graph representing the NAC dose response for chemoprotection against the cytotoxicity of alkylating chemotherapeutics.
  • Figure 2b shows the dose/response for NAC chemoprotection of BR96-DOX cytotoxicity in normal human gastric cells.
  • Figure 3 shows a graph representing protection against BR96-DOX gastric cell toxicity.
  • Figure 4 shows a graph representing protection against BR96-DOX gastric cell toxicity when cells are pretreated with BSO.
  • Figure 5 shows a graph representing the effect of BSO and NAC on BR96-DOX cytotoxicity.
  • Figure 6 shows another graph representing the effect of BSO and NAC on BR-96- DOX cytotoxicity.
  • Figure 7 shows a graph representing the effects of BSO on BR96-DOX cyctotoxicity.
  • Figure 8 shows another graph representing the effects of BSO on BR96-DOX cyctotoxicity.
  • Figure 9 shows an anatomical diagram of major arteries and the top level for placing the catheter for administration of the thiol-based chemoprotectant agent.
  • NAC and/or STS can reduce BR96-DOX toxicity in cultured gastric cells.
  • NAC and/or STS reduce BR96-DOX toxicity in normal GI tract cells in patients, even when the immunoconjugate is given in combination with conventional chemotherapeutic agents.
  • Figure 1 shows a graph representing the efficacy of BR96-DOX against human small cell lung carcinoma (SCLC) cells implanted in the brain of the nude rat.
  • a Kaplan- Meier survival graph is shown for rats with intracerebral xenografts of B.5 LX-1 cells with low Lewis Y antigen expression.
  • BR96-DOX immunoconjugate was administered with or without optimizing brain delivery using propofol anesthesia. There was a significant increase in survival in animals which received BR96-DOX following osmotic blood brain barrier diffusion (BBBD) (p ⁇ .0001). There was no difference in survival when BR96- DOX was administered either i.a. or i.v. without BBBD, and both groups were significantly better than the controls (BBBD + saline, no treatment, p ⁇ .0001). There was no difference in survival between either control group.
  • BBBD osmotic blood brain barrier diffusion
  • Figure 2b shows the dose/response for NAC protection against BR96-DOX toxicity in normal human gastric cells. Cytotoxicity was assessed in cultured normal human gastric cells (NHGC), using the WST colorometric assay for live cells. Cells were treated with approximately LD90 dose of BR96-DOX, immediately followed by NAC at the indicated concentrations. NAC was protective against BR96-DOX toxicity in the range of 1 mg/ml to 3 mg/ml, 10-fold higher than the concentration required for chemoprotection against the alkylating chemotherapeutics. Figures 3 and 4 represent graphically the percent viable gastric cells when treated with BR96-DOX alone and in combination with the various alternative chemoprotectants.
  • Figure 3 records the results without the administration of BSO while Figure 4 records the results after pretreatment with BSO to reduce intracellular glutathione levels.
  • a greater percentage of viable gastric cells were measured with the administration of NAC and BR96-DOX without the administration of BSO than with the administration of BSO (compare Figure 3 with Figure 4, particularly bar number 3 from left).
  • the administration of NAC with BR96-DOX increased the percentage of viable gastric cells regardless of BSO administration. Addition of GSH ethyl ester provided the second highest amount of viable gastric cells.
  • Figures 5 and 6 represent the effect of BSO and NAC on BR96-DOX cytotoxicity in gastric carcinoma cells. As the dosage of BR96-DOX is increased, fewer cells survive.
  • Figures 7 and 8 represent the administration of BR96-DOX either alone of in combination with BSO. As expected, the combination of BR96-DOX and BSO reduces the percentage of viable cells to zero.
  • GSH glutathione
  • BSO Buthionine Sulfoximine
  • NAC sodium thiosulfate
  • BSO sodium thiosulfate
  • Aortic infusion increases chemoprotectant delivery to systemic tissue with resultant bone marrow protection, but CNS delivery is negligible.
  • chemoprotection is valuable in the clinical setting if chemotherapy ( ⁇ Chemo) and chemoprotectant can be physically and/or temporally separated by intra-carotid infusion of alkylators and aortic infusion of chemoprotectant.
  • compositions and compounds of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, emulsifying, encapsulating, entrapping, or lyophilizing processes.
  • Pharmaceutical compositions for use in accordance with the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries that facilitate processing of the active compounds into preparations, which can be used pharmaceutically. Proper formulation is dependent upon the route of administration chosen.
  • the compounds of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers, such as Hank's solution, Ringer's solution, or physiological saline buffer.
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulary agents such as suspending, stabilizing and/or dispersing agents.
  • compositions for parenteral admi stration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • a therapeutically effective dose refers to that amount of the compound that results in a reduction in the development or severity of reduction in renal function. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical, pharmacological, and toxicological procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD50 and ED50. Compounds that exhibit high therapeutic indices are preferred. The data obtained from cell culture assays or animal studies can be used in formulating a range of dosage for use in humans.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
  • the individual physician in view of the patient's condition can choose route of administration and dosage the exact formulation. (Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics” , Ch. 1).
  • composition administered will, of course, be dependent on the subject being treated, on the subject's weight, the severity of the affliction, the manner of administration and the judgment of the prescribing physician.
  • the thiol-based chemoprotectant agent is administered intra-arterially according to the present invention and in order for systemic tissues to be exposed to an initial dose of the thiol-based chemoprotectant agent in high enough concentration by chemoprotective effective effect and before getting to the venous circulation and being eliminated by the liver.
  • Each thiol-based chemoprotectant agent such as NAC or STS
  • NAC or STS can be synthesized by conventional methods and are commercially available as a sterile solution. Pyrogen- free solutions for intra-arterial administration and those with buffers for physiologic pH administrations can be made by conventional techniques.
  • a NHGC cell line and a human gastric carcinoma cell line were obtained. Both cell lines were homogeneously highly positive for immunocytochemical staining with the BR96 antibody directed against the Lewis Y antigen. BSO enhanced cytotoxicity in the carcinoma cells, but did not increase toxicity in the normal gastric cells, the site of dose- limiting toxicity of BR96-DOX. Conversely, NAC protected the normal gastric cells from BR96-DOX toxicity, but did not protect the carcinoma cells.
  • the dose response curves for BR96-DOX and doxorubicin with or without the addition of buthionine sulfoximine (BSO) at a concentration of 100 ⁇ M were assessed.
  • the half maximal cytotoxic dose of BR96-DOX administered to AGS cells was approximately 1 ⁇ g/ml in the absence of BSO.
  • Pretreatment with BSO reduced the EC50 to approximately 0.6 ⁇ g/ml.
  • BSO treatment also increased the maximum cytotoxicity of BR96-DOX from 70% to 100 % cell kill.
  • Pretreatment with BSO also shifted the half maximal cytotoxic dose of doxorubicin from 0.1 ⁇ g/ml to approximately 0.05 ⁇ g/ml, but did not enhance the maximum cytotoxicity of doxorubicin, as doxorubicin alone killed nearly 100% of cells at maximal doses.
  • BSO did not significantly shift the EC50 of BR96-DOX in AGS carcinoma cells grown in an unsupplemented medium, but did increase the maximal cell kill from 75% to 100%.
  • BSO did not enhance the cytotoxicity of either BR96-DOX or doxorubicin.
  • Example 2 Chemoprotection in the gastric cells was examined by using NHGC normal gastric cells wherein the chemoprotective agent N-acetylcysteine (NAC) was at least partially protective against BR96-DOX cytotoxicity. The level of protection was variable, reducing cell kill by 25% in experiment 1, 95% in experiment 2, and 55% in experiment 3. NAC was protective independent of the presence of BSO. Other chemoprotective agents tested were not as effective as NAC, with only GSH ethyl ester yielding significant protection (cell kill reduced by 15-20%) and no significant effect of sodium thiosulfate or d- Methionine.
  • NAC N-acetylcysteine
  • NAC did reverse the enhanced cytotoxicity induced by BSO treatment, but did not alter the response to BR96- DOX in cells not treated with BSO.
  • the dose of NAC was 1200 mg/m2 and STS was 8 gm/m ⁇ .
  • White blood cell and platelet counts were obtained prior to, at 6 days and 9-10 days after chemotherapy.
  • BSO treatment for 3 days reduced blood and tissue GSH levels by 50-65% even in brain and intracerebral tumor in nude rats.
  • BSO pretreatment enhanced the bone marrow toxicity of combination chemotherapy.
  • Intraarterial administration of radiolabelled NAC in the right carotid artery resulted in high delivery to the right cerebral hemisphere, however, infusion of NAC via a new "aortic infusion" technique, retrograde in the left external carotid artery with the left internal carotid artery occluded to prevent infusion of the brain, reduced brain delivery to negligible levels while increasing systemic delivery.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode et une composition pharmaceutique destinées au traitement ou à l'atténuation des effets secondaires de la chimiothérapie cytotoxique utilisée contre les tumeurs cancéreuses. Cette méthode consiste à administrer un agent de chimio-prévention à base de thiols et un agent cytotoxique comportant un moyen de ciblage des glycoprotéines de Lewis Y.
PCT/US2001/027296 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique WO2002017962A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001287021A AU2001287021A1 (en) 2000-08-30 2001-08-30 Chemoprotectant for gastric toxicity
US10/363,150 US20040062764A1 (en) 2001-08-30 2001-08-30 Chemoprotectant for gastric toxicity
EP01966515A EP1365803A2 (fr) 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique
CA002420897A CA2420897A1 (fr) 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22986900P 2000-08-30 2000-08-30
US60/229,869 2000-08-30

Publications (3)

Publication Number Publication Date
WO2002017962A2 WO2002017962A2 (fr) 2002-03-07
WO2002017962A9 true WO2002017962A9 (fr) 2003-03-27
WO2002017962A3 WO2002017962A3 (fr) 2003-07-10

Family

ID=22862985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027296 WO2002017962A2 (fr) 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique

Country Status (4)

Country Link
EP (1) EP1365803A2 (fr)
AU (1) AU2001287021A1 (fr)
CA (1) CA2420897A1 (fr)
WO (1) WO2002017962A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
WO2004080429A2 (fr) * 2003-03-13 2004-09-23 Oregon Health & Science University Utilisation de compositions a base de thiol pour traiter une lesion des muqueuses
WO2005070026A2 (fr) * 2004-01-23 2005-08-04 Seattle Genetics, Inc. Polytherapie d'immunoconjugues medicamenteux
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
EP2881833B1 (fr) 2013-12-09 2019-06-19 Batz, S.Coop. Pédale réglable pour véhicules à moteur
WO2016044716A1 (fr) * 2014-09-19 2016-03-24 The American University In Cairo Polythérapie à base de nanoparticules

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Also Published As

Publication number Publication date
EP1365803A2 (fr) 2003-12-03
AU2001287021A1 (en) 2002-03-13
CA2420897A1 (fr) 2002-03-07
WO2002017962A3 (fr) 2003-07-10
WO2002017962A2 (fr) 2002-03-07

Similar Documents

Publication Publication Date Title
JP5242877B2 (ja) チオールをベースとする化学保護剤の投与
AU2001253919A1 (en) Administration of a thiol-based chemoprotectant compound
EP0220065A2 (fr) Conjugués de trichotécène
MXPA05012259A (es) Composicion de farmaco conjugado.
Hamblin et al. Biodistribution of charged 17.1 A photoimmunoconjugates in a murine model of hepatic metastasis of colorectal cancer
US20190350952A1 (en) Cytotoxic agents for the treatment of cancer
Remsen et al. Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model
US20040062764A1 (en) Chemoprotectant for gastric toxicity
ES2201109T3 (es) Conjugados de selenio para la preparacion de agentes farmaceuticos basados en radicales libres.
WO2002017962A9 (fr) Agent de chimio-prevention contre la toxicite gastrique
Liu et al. Cure of multidrug-resistant human B-cell lymphoma xenografts by combinations of anti-B4-blocked ricin and chemotherapeutic drugs
Sun et al. Anticarcinoma activity of a novel drug, 3-ethyl-3'-methyl-thiatelluracarbocyanine iodide (Te), a tellurium-containing cyanine targeted at mitochondria.
US20110046482A1 (en) Methods for reducing toxicities associated with medical procedures employing radiographic contrast agents
PT86960B (pt) Processo para a preparacao de conjugados de imunoglobulina
EP0213881B1 (fr) Application de molécules amphipathiques dans la radiovisualisation et thérapie par des conjugués d'anticorps mono- ou polyclonaux
Aiello et al. CBX-12: A low pH targeting alphalex™-exatecan conjugate for the treatment of solid tumors
US20100104628A1 (en) method of treating neuroblastoma
Bigner et al. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.
Kojima et al. Anti‐tumor activity of T‐2 toxin‐conjugated A7 monoclonal antibody (T‐2‐A7 MoAb) against human colon carcinoma
US7727560B2 (en) Treating cancer, liver, kidney, platelet and hemopoietic disorder or complication
Ota et al. Antitumor effect of monoclonal antibody-carboplatin conjugates in nude mice bearing human ovarian cancer cells
Herrlinger et al. Intrathecal therapy of leptomeningeal CEM T-cell lymphoma in nude rats with anti-CD7 ricin toxin A chain immunotoxin
ZA200208350B (en) Administration of a thiol-based chemoprotectant compound.
Levi Regional pharmacokinetics of the cytoprotective agent amifostine
CN115052608A (zh) 包含含有倍癌霉素衍生物的抗体-药物缀合物和硫代硫酸盐的组合

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2420897

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001966515

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10363150

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001966515

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001966515

Country of ref document: EP